Senior Scientist, Muscle Biology & Energy Metabolism
Regeneron Pharmaceuticals
Summary
We are seeking a Sr. Scientist to join the Obesity, Metabolism and Muscle Diseases Group to support the identification and validation of novel drug targets for metabolic disorders. This is a lab-based role for a scientist with a strong foundation in skeletal muscle physiology and energy metabolism. The ideal candidate can independently design and conduct in vitro and in vivo studies while collaborating and communicating efficiently across the group and other teams.
Job description
Discover your role
- Identify and implement novel areas, technologies and approaches for validating muscle-related targets and target modalities in metabolic disease drug discovery
- Design and conduct in vitro (e.g. primary and/or iPSC-derived myotube/myofiber models) and ex vivo (e.g. biomarker testing via ELISA) assays to support target validation
- Design and perform in vivo studies in animal models to characterize muscle and/or metabolic phenotypes, and provide mechanistic insights into the underlying biology
- Apply muscle histological approaches (e.g. IHC/IF, fiber-typing, in situ activity assays, in situ hybridization) to complement molecular and functional readouts
- Analyze data, draw scientifically sound conclusions and identify knowledge gaps
- Provide timely updates on scientific progress, communicating efficiently across teams and functions
- Thrive in a fast-paced, multi-project environment, staying detail-oriented and well-organized
- Work well both independently and as part of a team
- Bring curiosity and a desire to expand your areas of expertise as new questions arise
This role requires
- Ph.D. with a minimum of 3 years of post-doctoral research experience
- Broad expertise in skeletal muscle biology and energy metabolism (e.g., muscle bioenergetics, substrate utilization, mitochondrial function, muscle-organ crosstalk), with clear relevance to obesity, diabetes, lipid metabolism or endocrinology
- Ability to independently design and perform complex in vitro and in vivo studies, interpret data, and summarize results
- Passion and creativity to generate and pursue independent research ideas to advance drug discovery and development
- Excellent communication and presentation skills, with a strong record of scientific publications
- Preferred: experience with muscle histological techniques
- Preferred: strong understanding of human and mouse genetics
Requirements
- Ph.D. with a minimum of 3 years of post-doctoral research experience
- Broad expertise in skeletal muscle biology and energy metabolism (e.g., muscle bioenergetics, substrate utilization, mitochondrial function, muscle-organ crosstalk), with clear relevance to obesity, diabetes, lipid metabolism or endocrinology
- Ability to independently design and perform complex in vitro and in vivo studies, interpret data, and summarize results
- Passion and creativity to generate and pursue independent research ideas to advance drug discovery and development
- Excellent communication and presentation skills, with a strong record of scientific publications
- Preferred: experience with muscle histological techniques
- Preferred: strong understanding of human and mouse genetics
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.